Palazestrant
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Palazestrant
- Molecular weight
- 449.61
- Structure (SMILES)
- CCCN1CC(Oc2ccc([C@@H]3c4[nH]c5ccccc5c4C[C@@H](C)N3CC(C)(C)F)cc2)C1
- op 1250
- Op-1250
- OP-1250
- palazestrant
- Palazestrant
- palazestrant [INN]
- PALAZESTRANT [USAN]
- Palazestrant [WHO-DD]
- palazestrant inn
- palazestrant usan
- palazestrant who dd
- CAS registry numbers
- 2092925-89-6
- ChEMBL ID
- CHEMBL5314475
- InChIKey
- LBSFUBLFDCAEKV-XHCCPWGMSA-N
- PubChem compound IDs
- 135351887
- FDA ingredient codes (UNII)
- VU35KM56Q4
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -estr-; -estrant
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- NCT04505826
- NCT05266105
- NCT05508906
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 31.5
- Calculated partition coefficient (ALogP)
- 5.73
- Calculated partition coefficient (XLogP)
- 5.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 33
- Molecular formula
- C28H36FN3O
- Monoisotopic mass
- 449.28424094
- Natural product
- No
- Recorded assays
- 2
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (6)
- A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
In development for (3)
- Breast cancer Phase 1
- Breast carcinoma Phase 1
- Neoplasm Phase 2